In 2009, Hingorani et al. published results of their study that examined the effects of dasatinib, a dual Src-Abl kinase inhibitor, on in vitro proliferation, adhesion, and invasion of osteosarcoma cell lines and in preventing the development of spontaneous pulmonary metastases in an orthotopic murine osteosarcoma model. The gene discussed is SRC; the disease is osteosarcoma.